24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
(361)575-0611
(800)421-8825
Fax: (361)578-5500
Regular Business Hours: Monday - Friday 8am - 5pm
Every 3rd Thursday of the Month - Extended Hours Until 7 pm

Medical Disorders
Resources
Basic InformationLookupsLatest News
Half of Americans Still Not Wearing Masks When Out in Public: PollFor Maximum Effectiveness, De-Stress and Get Healthy Before Your COVID ShotUK Prime Minister Says British COVID Variant May Be More DeadlyImmune System May 'Remember' Infections From Previous CoronavirusesYou're More Likely to Maintain Social Distance If Your Friends Do: StudyExercise Doesn't Boost Health If You Stay Obese, Study FindsEven When Cancer Is in Remission, Patients' Risks of Severe COVID RiseFor Rising Number of People, Obesity Is a Literal HeadacheSevere Allergic Reaction Extremely Rare With Pfizer COVID Vaccine: StudyWill Vaccines Work Against the New Coronavirus Variants?More Than 200,000 Americans Have LupusKids Highly Likely to Transmit Coronavirus to Others: StudyArthritis Drug Tocilizumab Flops as COVID-19 TreatmentBiden Unveils Details of National Pandemic Response PlanDental Practices Rebound as U.S. Dentists Look Forward to COVID VaccineAHA News: COVID-19 Registries Offer Lessons Beyond the CoronavirusCOVID-19 Ups Complication Risks During ChildbirthWhen ICUs Near Capacity, COVID Patients' Risk for Death Nearly DoublesGetting the COVID Vaccine? A Good Night's Sleep Will HelpAmerica Sees COVID Deaths Top 400,000, While New Variants Worry ScientistsNasal Spray COVID Vaccine Shows Promise in Animal TrialsFried Food a Big Factor in Heart Disease, StrokePromising Steps Toward Retinal Cell Transplants to Fight BlindnessDo You Socially Distance? Your Income Might MatterIf a Nursing Home Resident Gets a COVID Shot, Can Their Families Visit Them Now?Vision Problems? Here's a Guide to Which Specialist Is Right for YouShould Your Child Get a COVID Test?New Hope Against Diseases Marked by Progressive Scarring of Lung TissueAHA News: What Heart and Stroke Patients Should Know About COVID-19 VaccinesCOVID Pandemic Shortened U.S. Life Expectancy by More Than a YearShorter COVID Quarantine for College Athletes a Good Idea, Study FindsWhat Happened to the Flu This Year?3 Steps Could Nearly Eliminate COVID Infections on College Campuses: StudyPharmacy Chains Ready to Supply COVID-19 Vaccines to AmericansI've Already Had COVID-19, Do I Need the Vaccine?What Will COVID-19 Look Like Years From Now?First Computer Model of Entire COVID Virus Will Aid ResearchStopping Common Heart Meds Could Be Risky for Kidney PatientsU.S. COVID Vaccine Rollout Nears 1 Million Doses Per DayJohnson & Johnson's One-Dose COVID Vaccine Promising in Early TrialLockdowns' Benefits for Air Quality Weren't as Big as Thought: StudyPeople's 'Microbiomes' Might Influence COVID-19 Severity: StudyNew Insights Into How COVID-19 Damages the BrainCollege Campuses Are COVID 'Superspreaders,' Study FindsStuck at Home, Suffering With COVID? Experts Offer Guidance on CareCOVID Daily Death Toll Sets New U.S. Record, Soars Past 4,400AHA News: Registries Could Offer Insight Into COVID-19's Impact on College Athletes' HeartsResearch Reveals Why COVID Pneumonia Is More DeadlyPandemic Is Tied to Big Rise in U.S. Heart DeathsCommon Diabetes Meds Tied to Serious COVID-19 Complication
Questions and AnswersLinks
Related Topics

Diabetes

Another Study Casts Doubt on 'Convalescent Plasma' as COVID-19 Treatment

HealthDay News
by By Ernie Mundell HealthDay Reporter
Updated: Nov 25th 2020

new article illustration

WEDNESDAY, Nov. 25, 2020 (HealthDay News) -- Early in the COVID-19 pandemic, anecdotal reports suggested that infusing very sick patients with the blood plasma of people who'd survived the disease might help boost outcomes.

But study findings released Nov. 24 in the New England Journal of Medicine, along with disappointing results from prior trials, suggest that those initial hopes may have been unfounded.

The new study was conducted by researchers in Argentina. It compared outcomes for 228 hospitalized COVID-19 patients who got an infusion of so-called "convalescent plasma" against those of 105 patients who did not (the "placebo group"). All were so sick as to have developed pneumonia.

However, one month later, "no significant difference was noted between the convalescent plasma group and the placebo group" in terms of clinical outcomes, with about 11% of patients dying in both groups, according to a team led by Dr. V.A. Simonovich of the Italian Hospital of Buenos Aires.

The theory behind the use of survivors' blood plasma in people battling COVID-19 is that plasma contains immune system agents that might aid recipients in their fight against the disease.

But a prior study from India — this time in patients with "moderate" COVID-19 — also found little benefit of the treatment in stopping illness from progressing to a more severe stage. That study was led by Dr. Anup Agarwal, of the Indian Council of Medical Research in New Delhi, and was published Oct. 22 in the BMJ.

According to one U.S. expert unconnected to either trial, it may be time to give up on convalescent plasma as a viable COVID-19 treatment.

"There have been several major trials that have shown the same results: Convalescent plasma does not seem to have an impact on the course of COVID-19," said Dr. Mangala Narasimhan. She's senior vice president and director of Critical Care Services at Northwell Health, in New Hyde Park, N.Y.

Narasimhan also noted that in the Argentinian trial, "even with good measurement of the amount of antibody they were giving people [in the transfusions], there was no benefit seen."

She believes that other treatments should remain first-line options for severe COVID-19.

"The new monoclonal antibodies will give a more targeted and reliable antibody load to COVID-19 patients and may have an impact on the course of disease if given early after positive testing," Narasimhan said.

More information

Find out more about how to treat coronavirus at home from the U.S. Centers for Disease Control and Prevention.

SOURCES: New England Journal of Medicine, Nov. 24, 2020; Mangala Narasimhan, DO, SVP, director of critical care services, Northwell Health, New Hyde Park, N.Y.